BioStem pushes Catalyze payment deadline to August 13, 2026, with up to $1M in extension fees
BSEM sits 24% above its 52-week low of $3.093 on light trading volume (0.1× avg).
Summary
BioStem Technologies extended the deadline to pay up to $10 million for the Catalyze wound care device to August 13, 2026, with a possible further extension to September 15, 2026, in exchange for up to $1 million in non-refundable extension fees. The company must secure debt or equity financing to make the payment.
Key Events · Financing and Capital Events · BSEM
-
Clearance Payment Deadline Extended
The deadline to pay BioTissue up to $10 million for the Catalyze product rights was extended from July 6, 2026, to August 13, 2026, with possible further extensions to September 15, 2026, subject to interim payments.
-
Extension Fees Total Up to $1M
BioStem paid $500,000 on July 6, 2026 ($250,000 extension fee, $250,000 advance against the Clearance Payment). An additional $500,000 is due by August 13, 2026, if the Clearance Payment isn't made, to extend to August 31, 2026, and then to September 15, 2026.
-
Forfeiture Risk if Payment Not Made by September 15
If the full Clearance Payment is not received by September 15, 2026, all extension payments are forfeited and the $10 million becomes immediately due and payable.
-
Financing Required to Close
The company plans to finance the Clearance Payment through a combination of debt and equity financing, and its ability to make the payment is dependent on closing such financings.
Analysis · BSEM · Life Sciences
To keep its deal for the Catalyze wound care device alive, BioStem Technologies amended its asset purchase agreement with BioTissue, extending the deadline for a $10 million payment tied to FDA clearance. The company paid $500,000 on July 6, 2026, securing an extension to August 13, 2026, and may pay another $500,000 to push the deadline to September 15, 2026. If the full payment isn't made by then, all extension fees are forfeited and the $10 million becomes immediately due. This amendment underscores the company's urgent need to secure financing, against a backdrop of a going concern warning and a recent $8.8 million quarterly loss.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSEM was trading at $3.84 on OTC in the Life Sciences sector, with a market capitalization of approximately $62.7M. The 52-week trading range was $3.09 to $12.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.